Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167630 | 1.00 | L3MBTL1 (0.66) | L3MBTL1MAPTTDP1CYP1A2CYP2C19 | |
| SCHEMBL11874439 | 0.94 | L3MBTL1 (0.64) | L3MBTL1MAPTTDP1CYP1A2CYP2C19 | |
| SCHEMBL11662071 | 0.92 | L3MBTL1 (0.62) | L3MBTL1MAPTTDP1CYP1A2CYP2C19 | |
| SCHEMBL2482690 | 0.91 | L3MBTL1 (0.71) | L3MBTL1MAPTTDP1CYP1A2CYP2C19 | |
| SCHEMBL3790085 | 0.89 | L3MBTL1 (0.59) | L3MBTL1MAPTTDP1CYP1A2CYP2C19 | |
| Di(Hydroxyethyl)Ether SCHEMBL2482687 | 0.88 | L3MBTL1 (0.59) | L3MBTL1MAPTTDP1CYP1A2CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL27524671 | 0.88 | L3MBTL1 (0.58) | L3MBTL1MAPTTDP1CYP1A2CYP2C19 | |
| SCHEMBL9808263 | 0.84 | L3MBTL1 (0.68) | L3MBTL1MAPTTDP1CYP1A2CYP2C19 | |
| 1,2-Dibutoxybenzene SCHEMBL1226749 | 0.84 | CYP1A2 (0.72) | L3MBTL1MAPTTDP1CYP1A2CYP2C19 | |
| 1,2-Dibutoxybenzene SCHEMBL29428927 | 0.84 | CYP1A2 (0.72) | L3MBTL1MAPTTDP1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079901-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-03-19 | — | — | US | disclosed |
| EP-2588197-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8703759-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2012058132-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| US-7521581-B2 | Catalyst composition and process for producing cross-coupled compound using same | TOSOH CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | TOSOH CORPORATION | 2006-10-05 | — | — | US | disclosed |
| EP-1707263-A1 | Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same | Tosoh Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-6984645-B2 | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| WO-2004105738-A2 | USE OF TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-12-09 | — | — | WO | disclosed |
| US-6479709-B1 | Process for the production of styrene derivative | TOSOH CORPORATION (JP) | 2002-11-12 | — | — | US | disclosed |
| US-6472567-B2 | REACTING A GRIGNARD REAGENT PREPARED FROM A SUBSTITUTED PHENYL HALIDE, ESPECIALLY A TERT-BUTOXYPHENYL HALIDE, WITH A VINYL HALIDE IN THE PRESENCE OF A MANGANESE, IRON, COBALT OR RHODIUM CATALYST; PRODUCT FREE FROM BIPHENYL. | TOSOH CORPORATION (JP) | 2002-10-29 | — | — | US | disclosed |
| US-20020026084-A1 | Process for the production of styrene compound, and styrene compound free from biphenyl | TOSOH CORPORATION (JP) | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | L3MBTL1 3585/4885MAPT 4213/4885TDP1 3574/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | L3MBTL1 3838/4885MAPT 3312/4885TDP1 4196/4885 |
| US-20020026084-A1 | Process for the production of styrene compound, and styrene compound free from biphenyl | RNF4, GRHPR, SBDS | L3MBTL1 863/4885MAPT 1929/4885TDP1 3812/4885 |
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | C5, TST, PYM1 | L3MBTL1 3243/4885MAPT 4629/4885TDP1 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.